Fusion proteins between the human 5-hydroxytryptamine (5-HT) 1A receptor and either wild type or certain pertussis toxinresistant forms of G o1 ␣ and G i1 ␣ display constitutive GTPase activity that can be inhibited by the inverse agonist spiperone. Addition of recombinant regulator of G protein signaling (RGS) 1 or RGS16 to membranes expressing these fusion proteins resulted in elevation of this constitutive GTPase activity without significantly altering the binding affinity of antagonist/inverse agonist ligands. For a 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ fusion protein the increase in basal GTPase activity was greater than 4-fold. Enzyme kinetic analysis demonstrated that the effect of RGS1 was as a GTPase-activating protein for the fusion construct. In the presence of the RGS proteins, both agonists and inverse agonists produced much more robust regulation of high-affinity GTPase activity than in their absence. This allowed detection of the partial agonist nature of WAY100635, which has been described previously as a neutral antagonist at the 5-HT 1A receptor. Of a range of ligands studied, only haloperidol functioned as a neutral ligand in the presence of RGS1. These studies show that addition of a recombinant RGS protein provides a simple and novel means to elevate the fraction of basal membrane GTPase activity contributed by the constitutive activity of a receptor. By so doing, it also greatly enhances the ability to detect and analyze the effects of inverse agonists and to discriminate between neutral ligands and those with low levels of positive intrinsic efficacy.
inverse agonists produced much more robust regulation of high-affinity GTPase activity than in their absence. This allowed detection of the partial agonist nature of WAY100635, which has been described previously as a neutral antagonist at the 5-HT 1A receptor. Of a range of ligands studied, only haloperidol functioned as a neutral ligand in the presence of RGS1. These studies show that addition of a recombinant RGS protein provides a simple and novel means to elevate the fraction of basal membrane GTPase activity contributed by the constitutive activity of a receptor. By so doing, it also greatly enhances the ability to detect and analyze the effects of inverse agonists and to discriminate between neutral ligands and those with low levels of positive intrinsic efficacy.
Constitutive activity of G protein-coupled receptors (GPCRs) has been one of the most highly studied topics in pharmacology in the recent past (Leurs et al., 1998; Pauwels and Wurch, 1998; de Ligt et al., 2000) . Such studies have provided novel insights into the mechanisms of action of GPCRs and introduced the term inverse agonist for ligands able to suppress this activity (Milligan et al., 1995) . So widespread have the studies been that compounds, generally now described as neutral antagonists, that bind receptors but fail to alter their activity are considered to be relatively uncommon.
Direct measures of regulation of the activation of a G protein by a GPCR can be provided by monitoring either exchange of a poorly hydrolyzed analog of GTP for GDP on the G protein ␣-subunit (Wieland and Jakobs, 1994) or the subsequent hydrolysis of authentic GTP by the GTPase activity of this subunit (Gierschik et al., 1994) . This GTPase activity and its regulation can be analyzed using basic enzyme kinetics. However, when using both purified G proteins and membrane preparations, the rate of GTP hydrolysis has routinely been noted to be much slower than the rate of deactivation of a range of G protein-mediated events in vivo. Such discrepancies informed searches for GTPase-activating proteins (GAPs) capable of accelerating the turn-off reaction. The largest family of such GAPs for heterotrimeric G proteins in mammals are the regulators of G protein signaling (RGS) proteins (De Vries et al., 2000) , comprising more than 20 polypeptides that contain a highly conserved RGS domain within their sequence. These act as GAPs for many G proteins and can be shown to alter the effectiveness of downstream signal transduction (Berman et al., 1996; Druey et al., 1996; Doupnik et al., 1997; Hepler et al., 1997; Saitoh et al., 1997) . Wide-ranging experiments (Berman et al., 1996) and the crystal structure of the core RGS domain of RGS4 complexed with G i1 ␣ (Tesmer et al., 1997) indicated that the Financial support for this work was provided by the Medical Research Council and the Wellcome Trust. P.W. is a recipient of a "CASE" studentship from the Biotechnology and Biosciences Research Council. mechanism of these proteins was via stabilization of the transition state required for GTP hydrolysis.
For many native GPCRs in cell membranes, their degree of constitutive activity is modest. Thus, when measuring inhibition of GTPase activity by potential inverse agonists, it may be difficult to obtain precise information. Because an RGS protein must be expected to function as a GAP for GTP loaded by the constitutive activity of a GPCR and after agonist activation, we reasoned that RGS proteins may be used to enhance the dynamic range of GTPase activity arising from the presence of constitutively activated GPCRs.
We demonstrate that this is the case, that the extent of this effect varies dependent upon the identity of the G protein studied, that it can provide a substantially more robust analysis of compounds with inverse agonist activity, and that this approach is well suited to the study of ligands with positive but low intrinsic activity.
tips. About 20 clones of each cDNA were picked and grown in 1 ml/well G418 medium (400 g/ml). Clones were amplified, membrane preparations were made, and their binding of
Preparation of Membranes. Plasma membrane-containing P2 particulate fractions were prepared from cell pastes that had been stored at Ϫ80°C after harvesting. Cell pellets were resuspended in Tris/EDTA buffer [10 mM Tris HCl, pH 7.5, and 0.1 mM EDTA], and rupture of the cells was achieved with 25 strokes of a hand-held Teflon-on-glass homogenizer. Unbroken cells and nuclei were removed by centrifugation at low speed (1600 rpm) in a refrigerated microcentrifuge. The supernatant fraction was then centrifuged at 50,000 rpm for 30 min in an Optima TLX ultracentrifuge with a TLA100.2 rotor (Beckman Coulter, Inc., Fullerton, CA). The pellets were resuspended in Tris/EDTA buffer to a final protein concentration of 1 mg/ml and stored at Ϫ80°C until required.
[ 3 H]WAY100635 Binding Studies. Binding assays were performed by adding 5 g of membrane protein to an assay buffer (20 mM HEPES, 10 mM MgCl 2 , 0.1% ascorbic acid, and 10 M pargyline, pH 7.4) containing [
3 H]WAY100635 (0.25-12 nM). Nonspecific binding was determined in parallel in the presence of 100 M 5-HT. Samples were incubated at 30°C for 40 min and then terminated by rapid filtration through GF/C filters. The filters were washed three times with 5 ml of ice-cold wash buffer (20 mM HEPES, 10 mM MgCl 2 , and 0.1% ascorbic acid, pH 7.4) and then counted. In a number of experiments, recombinant RGS1 was also added to the binding assays. In competition binding assays, [
3 H]WAY100635 was present at 1 nM.
High-Affinity GTPase Assays. High-affinity GTPase assays were performed essentially as described previously (Wise et al., 1997a (Wise et al., , 1997b Wise and Milligan, 1997) adapted to a 96-well microtiter plate assay (Hoffmann et al., 2001) . Nonspecific GTPase activity was assessed by parallel assays in the presence of 100 M GTP. GTPase saturation data were analyzed by nonlinear regression using Prism version 2.01 (GraphPad Software, San Diego, CA).
Purification of GST-Tagged RGS1 and RGS16. GST-RGS1 (Denecke et al., 1999) was kindly donated by Dr. A. Meyerdierks (Department of Medical Microbiology, Medizinischer Hochschule, Hannover, Germany). The full coding region of the human RGS1 gene except the initiation codon was cloned in-frame in the BamHI and SalI sites of the vector pGEX4T1 (Amersham Biosciences).
GST-RGS16 (Chen et al., 1997) was kindly donated by Dr. C. W. Fong (Institute of Molecular and Cell Biology, Singapore). In essence, the GST-RGS16 was constructed in a similar way as for RGS1. The coding region of the RGS16 gene was fused to the GST gene of the vector pGEX-2TK2 (derived from pGEX-2KT, Amersham Biosciences) with modifications in the multiple cloning region.
GST-RGS fusion proteins were isolated from transformed Escherichia coli BL21 cells. In brief, E. coli BL21 cells were transformed with the appropriate plasmids and plated on LB agar plates containing 100 g/ml ampicillin. The next day, cells were washed from the plate and used to inoculate 400 ml of LB medium (supplemented with 100 g/ml ampicillin) at an OD 660 of 0.1. Cells were grown for 1 h before induction of the expression of the GST-RGS fusion proteins by addition of 1 mM isopropyl ␤-D-thiogalactoside. Cells were allowed to express the fusion protein for 4 h, after which the cells were harvested by centrifugation. Pellets were stored at Ϫ80°C or used immediately for GST affinity purification of the GST-tagged proteins. Pellets were resuspended in BugBuster solution (Novagen, Madison, WI) with 5 ml/g wet tissue and containing 10 l of Benzonase (Novagen) to reduce viscosity. Cells were incubated with 1 mg/ml lysozyme for 30 min on ice followed by sonication to disrupt the cells (4 ϫ 30-s pulses). Dithiothreitol (5 mM) was added to the lysed cells before the addition of 200 l of 50% (w/v) slurry of glutathione-Sepharose 4B (Amersham Biosciences). Samples were incubated at room temperature on a rotary wheel for 30 min and the Sepharose harvested by centrifugation at 500g. The beads were washed three times with 2 ml of ice-cold phosphate-buffered saline and the GST fusion proteins eluted from the beads with 20 mM reduced glutathione in a Tris-HCl buffer, pH 7.4. Purity of the isolated protein was visually inspected after SDS-PAGE. Protein amounts were determined according to Bradford (1976) after precipitation of a small amount of protein with 6% trichloroacetic acid to remove the glutathione.
Miscellaneous. All experiments were performed on a minimum of three occasions using cells or membrane preparations derived from different cell passages. Where appropriate, data are presented as means Ϯ S.E.M.
Results
Membranes stably expressing a fusion protein between the human 5-HT 1A receptor and a pertussis toxin-resistant form of G i1 ␣ in which cysteine 351 of the G protein was replaced by isoleucine have higher levels of basal high-affinity GTPase activity than those expressing a similar level of a fusion protein between the 5-HT 1A receptor and a form of G i1 ␣ in which this cysteine is replaced by glycine (Kellett et al., 1999) . This difference reflects a constitutive capacity of the 5-HT 1A receptor to activate (Cys 351 Ile)G i1 ␣ because the 5-HT 1A receptor inverse agonist spiperone (Barr and Manning, 1997; Newman-Tancredi et al.,1997a Kellett et al., 1999; Milligan et al., 2001 ) is able to reduce basal highaffinity GTPase activity in these membranes but not in those expressing the 5-HT 1A receptor-(Cys 351 Gly)G i1 ␣ fusion protein (Kellett et al., 1999) .
The 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣ fusion protein could be immunodetected as an 85-kDa polypeptide (Fig. 1A) . Addition of 1 M recombinant RGS1 (Hoffmann et al., 2001 ) to membranes of pertussis toxin-pretreated cells stably expressing this construct resulted in an increase in basal highaffinity GTPase activity (Fig. 1A ) and a greatly enhanced capacity to measure stimulation of GTPase activity upon addition of increasing concentrations of 5-HT (Fig. 1A) . The 5-HT 1A receptor selective agonist 8-OH-DPAT was as effective as 5-HT (Fig. 1B) , and 1 M recombinant RGS16 (Hoffmann et al., 2001 ) also enhanced the effects of the agonists (Fig. 1B) . This was not observed upon equivalent additions of the RGS proteins to membranes expressing the 5-HT 1A receptor-(Cys 351 Gly)G i1 ␣ fusion protein or to membranes of mock-transfected cells (data not shown). We also constructed and stably expressed fusion proteins between the human 5-HT 1A receptor and both (Cys 351 Ile)G o1 ␣ and (Cys 351 Gly)G o1 ␣. After pertussis toxin treatment and membrane preparation, addition of recombinant forms of either RGS1 (Fig. 2 ) or RGS16 (data not shown) also elevated basal high-affinity GTPase activity in the membranes expressing the 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ fusion protein (Fig. 2 ). This polypeptide could also be immunodetected as an 85-kDa polypeptide (Fig. 2) . As before, the RGS proteins had little effect in membranes expressing the Gly 351 -containing version of this fusion protein (data not shown). Noticeably, however, compared with the effects (less than 2-fold) on basal GTPase activity in membranes expressing 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣ (Fig. 1A ), 1 M RGS1 increased basal activity some 4-fold in membranes expressing the 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ fusion protein (Fig. 2) . The stimulatory effects of both 5-HT ( Fig. 2 ) and 8-OH-DPAT (data not shown) on GTPase activity were again greatly enhanced compared with those observed in the absence of the RGS (Fig. 2) .
Half-maximal effects of RGS1 required some 50 nM for 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ and some 90 nM for 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣ (Fig. 3) . Enzyme kinetic analysis of the high-affinity GTPase activity indicated that increasing concentrations of RGS16 elevated the V max of both basal ( (Table 1) , it did so without producing an alteration in apparent K m for GTP (Table 1) . By contrast, both in the absence and the presence of 5-HT, the effects of the RGS proteins reflected a combination of increased GTPase V max and in- Ile) G i1 ␣ fusion protein were pretreated with pertussis toxin (25 ng/ml, 24 h) before harvest and membrane preparation. The capacity of varying concentrations of 5-HT to regulate high-affinity GTPase activity was measured in the absence (open symbols) (absence of 5-HT ϭ 28.9 Ϯ 0.6 pmol/min/mg membrane of protein) and presence (filled symbols) (absence of 5-HT ϭ 47.6 Ϯ 0.1 pmol/min/mg membrane of protein) of 1 M recombinant RGS1. GTPase activity was measured at 0.5 M GTP. Inset, membranes from parental HEK 293 cell (A) and those expressing either 5-HT 1A receptor-(Cys Table 1 ). To ensure that the effects of the RGS proteins were not restricted to the fusion proteins containing the Cys 351 Ile mutations similar experiments were performed on membranes expressing fusion proteins between the 5-HT 1A receptor and wild-type forms of either G i1 ␣ or G o1 ␣. For both of these constructs RGS1 markedly enhanced basal GTPase activity and synergistically increased the effect of a maximally effective concentration of 5-HT in membranes of cells that had not been pretreated with pertussis toxin (Fig. 5) .
This effect of the RGS proteins was extremely useful in demonstrating weak agonism of WAY100635. In membranes expressing either the 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ or the 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣ fusion proteins, this compound acted as either a neutral antagonist or a very weak partial agonist (Fig. 6 ) with little ability to alter basal GTPase activity. However, in the additional presence of 1 M RGS1 WAY100635 clearly functioned as a low-efficacy partial agonist ( Fig. 6 ; Table 1 ). Furthermore, the enhanced sensitivity imbued to detection of efficacy in the presence of an RGS protein allowed good estimates to be obtained for EC 50 for WAY100635 (2.8 -4.6 ϫ 10 Ϫ9 M) (Fig. 6) . This was not possible without addition of the RGS. In the absence of RGS1, enzyme kinetic analysis showed that the effects of 1 M WAY 100635 were, like 5-HT, achieved by an increase in V max without alteration in K m for GTP (Table 1 ). In the presence of RGS1, WAY100635 further increased enzyme activity over that achieved by RGS1 alone but had little or no further effect on the K m for GTP (Table 1) . Importantly, addition of RGS1 to membranes expressing these fusion proteins had little effect of the affinity or maximal capacity of [ 3 H]WAY100635 to bind to the receptor ( Fig. 7 ; data not shown).
Because the majority of wild-type receptors display relatively low levels of constitutive activity Rossier et al., 1999) , it is often difficult to monitor functional differences between inverse agonists and neutral antagonists. Mutational alteration of the receptor is often required to boost the level of constitutive activity for such studies Samama et al., 1993; Scheer and Cotecchia, 1997) . However, as RGS proteins function to catalyze the GTP hydrolysis rate (De Vries et al., 2000) , the elevated GTPase activity of the fusion proteins in the absence of ligands but the presence of RGS reflects a response to constitutive loading of GTP onto the fusion protein. Dependent on their relative intrinsic activity, therefore, inverse agonists would be expected to reduce or eliminate the effect of the RGS proteins. If this is so, then the capacity to detect inverse agonism should be markedly improved in the presence of an RGS. To test this hypothesis, we measured the ability of varying concentrations of the previously characterized 5-HT 1A receptor inverse agonist spiperone to reduce basal high-affinity GTPase activity in membranes expressing either the 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣ or the 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ fusion proteins in the absence and presence of RGS1. As anticipated from previous studies (Kellett et al., 1999; Milligan et al., 2001) , in the absence of RGS1, spiperone inhibited basal GTPase activity in membranes expressing the 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣ fusion protein by some 50% with an EC 50 value of 6.7 ϫ 10 Ϫ8 M (Fig. 8A). In the presence of 1 M RGS1, spiperone displayed a similar EC 50 value (4.6 ϫ 10 Ϫ8 M). However, with the elevation in constitutive, receptor-mediated GTPase activity, this was substantially easier to measure (Fig. 8A) . The precision of measurement was even more pronounced when the experiments were repeated using the 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ fusion protein. Although spiperone could be shown to be an inverse agonist at this construct, in the absence of the RGS, this was difficult to quantitate with precision (Fig. 8B) . Because the 4-fold elevated basal activity in these membranes observed on addition of RGS1 was attenuated almost completely by spiperone, this was easy to measure and provided an EC 50 value of 3.2 ϫ 10 Ϫ8 M for the ligand (Fig. 8B) . Importantly, the ability and potency of spiperone to compete with [ 3 H]WAY100635 for binding to the fusion constructs was also unaltered by the presence of the RGS ( Fig. 8C; data not shown) .
To explore the basis of the effect of the RGS proteins, GTPase assays were again performed at a wide range of concentrations of GTP. Basal activity in membranes expressing the 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ fusion protein was adequately described by a single function with K m for GTP in the region of 100 nM. In the presence of 1 M RGS1, the increase in basal activity was shown to represent both an increase in GTPase V max and an increase in the observed K m for GTP (Fig. 9) . Spiperone, at a maximally effective concentration, reduced V max and returned the observed K m for GTP to a value close to that of the basal state (Fig. 9) .
A series of other ligands with affinity at the 5-HT 1A receptor was also examined. For methiothepin, (ϩ)-butaclamol, and chlorpromazine, inverse agonist activity could be easily detected at both the 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣ and the 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ fusion proteins when the assays were performed in the presence of RGS1 (Fig. 10) . These compounds were without effect on basal GTPase activity in membranes of parental HEK 293 cells (data not shown). Data on inverse agonism of these compounds was either impossible to quantitate effectively [5-HT 1A receptor-(Cys 351 Ile)G o1 ␣] (Fig. 10A) or was substantially less convincing [the 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣] (Fig. 10B) when the assays were performed in the absence of an RGS. Only in the case of haloperidol were conclusions that it functioned as an essentially neutral ligand at the 5-HT 1A receptor-fusion proteins confirmed when the assays were also performed in the presence of RGS1 (Fig. 11A) . This was not a reflection of a lack of binding of haloperidol to the fusion proteins (Fig.  11B) . A small inhibition of GTPase activity was noted for the highest concentrations of haloperidol tested (Fig. 11A ), but this is probably a nonspecific effect because these concentrations are not consistent with the affinity of haloperidol at the 5-HT 1A receptor (Fig. 11B) . High concentrations of haloperidol were also able to reverse the inhibition of GTPase activity produced by spiperone (Fig. 11C) , confirming that spiperone Discussion 5-HT is a key neurotransmitter, and the 5-HT 1A receptor is an important target for drug action. This reflects that presynaptic 5-HT 1A receptors in the raphe nuclei control 5-HT release throughout the brain and that postsynaptic 5-HT 1A receptors are important in functions that include memory and stress modulation. Indeed, gene knockout studies have confirmed key roles for the 5-HT 1A receptor in anxiety and anti-depressive actions (Heisler et al., 1998; Ramboz et al., 1998) . The capacity of recombinant RGS proteins to elevate basal high-affinity GTPase activity in membranes expressing fusion proteins between the 5-HT 1A receptor and each of wild type and pertussis toxin resistant (Cys 351 Ile) forms of both G i1 ␣ and G o1 ␣, but not in membranes from mock transfected cells, provides clear evidence for constitutive information transfer between this receptor and these G proteins. It is noteworthy that we have previously recorded constitutive activity of the 5-HT 1A receptor-(Cys 351 Ile) G i1 ␣ fusion protein but not for a similar construct containing (Cys 351 Gly)G i1 ␣ (Kellett et al., 1999) because we have also demonstrated that the interactions between GPCRs and G i -family G proteins are of higher affinity and more conducive to productive information transfer when a hydrophobic amino acid is used to replace the pertussis toxin-sensitive cysteine (Waldhoer et al., 1999; Moon et al., 2001a) . RGS1 was half-maximally effective at some 50 nM, a concentration akin to that recently noted for its regulation of an agonist activated ␣ 2A -adrenoceptor-G o1 ␣ fusion protein (Hoffmann et al., 2001) . Interestingly, this effect of RGS1 was much more pronounced in membranes expressing 
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at ASPET Journals on June 16, 2017 molpharm.aspetjournals.org the G o1 ␣ rather than the G i1 ␣-containing fusion protein. Again, this was previously noted for agonist stimulation of ␣ 2A -adrenoceptor-containing fusion proteins (Cavalli et al., 2000) and may indicate that in a membrane environment, it is a more efficient GAP for G o1 ␣ than G i1 ␣.
Constitutive activity of GPCRs and the capacity of this to be suppressed by inverse agonists has been very actively studied in recent years. However, because the level of constitutive activity of many wild-type receptors is relatively low, many of these studies have used mutationally modified receptors with enhanced agonist-independent activity to allow amplification of the constitutive signal. There is, however, clear evidence that at least certain GPCRs do display significant constitutive activity in vivo and that regulation of this activity may have pathophysiological significance (Morisset et al., 2001 ). An attractive feature of the use of recombinant RGS proteins to boost the constitutive GTPase activity of the 5-HT 1A receptor fusion proteins is that their accepted mechanism of action is to promote the rate of hydrolysis of GTP. By contrast, receptor ligands regulate the rate of guanine nucleotide exchange of the G protein (Gilman, 1987) . Because nucleotide exchange is the rate-limiting step in the activation/deactivation cycle (Gilman, 1987) , then the effect of the RGS is simply to boost the capacity of the fusion protein to load GTP in response to either constitutive or agonist-induced activity. Proof of this mechanism of action of RGS1 and RGS16 on the constitutive activity of the 5-HT 1A receptor-(Cys 351 Ile) G o1 ␣ fusion protein was obtained by enzyme kinetic analysis of the GTPase activity. Addition of these RGS proteins increased both GTPase V max and the K m for GTP. We have previously shown that acceleration of the GTP hydrolytic activity must be accompanied by both of these features (Cavalli et al., 2000; Hoffmann et al., 2001) . It was, thus, anticipated that an inverse agonist would restore both of these features and this was observed when a maximally effective concentration of spiperone was added in concert with RGS1 (Fig. 9) . We selected spiperone for these studies Ile) G o1 ␣ fusion protein was measured at a wide range of concentrations of GTP in the absence (open symbols) or presence (filled symbols) of 100 M spiperone. In the example displayed, GTPase V max in the basal state was 23.4 Ϯ 0.9 pmol/min/mg membrane of protein, and the measured K m for GTP was 145 Ϯ 11 nM. RGS1 alone increased the GTPase V max to 146 Ϯ 11.0 pmol/min/mg membrane of protein and increased markedly the K m for GTP (492 Ϯ 61 nM). Spiperone reduced basal GTPase (12.7 Ϯ 1.5 pmol/min/mg membrane of protein) without altering the K m for GTP (100 Ϯ 25 nM). In the presence of both RGS1 and spiperone, the values were V max 23.6 Ϯ 2.7 pmol/min/mg membrane of protein and K m 143 Ϯ 33 nM. because it has previously been well characterized as an inverse agonist at the 5-HT 1A receptor. These observations and the related effects of added RGS proteins on 5-HT stimulated GTPase activity raise an interesting issue. When 5-HT is added to membranes expressing either the 5-HT 1A receptor-(Cys 351 Ile) G o1 ␣ or the 5-HT 1A receptor-(Cys 351 Ile) G i1 ␣ fusion proteins the effect is to increase GTPase V max , but it has little effect on the observed K m for GTP (Table 1 ; Kellett et al., 1999) . However, with addition of the RGS proteins, as with the situation with basal activity, both the GTPase activity and the apparent K m for GTP are markedly increased. These observations imply that the membrane preparations themselves have little functionally relevant RGS activity. It is currently unclear whether this reflects low levels of cellular expression of RGS proteins or whether cell homogenization and membrane preparation results in removal of much of the endogenous RGS. This will be explored in future studies, but clearly RGS proteins are, at best, peripheral membrane proteins with anchorage to the membrane being provided by combinations of post-translational acylation, cysteine string motifs, N-terminal amphipathic ␣-helices and possibly other means Druey et al., 1999; De Vries et al., 2000) . It also seems that a number of RGS proteins are not confined to the plasma membrane but are molpharm.aspetjournals.org present in cellular compartments including the cytosol, Golgi, and nucleus (Wylie et al., 1999; Chatterjee and Fisher, 2000) .
In the recent past, fusion proteins between receptors and G protein ␣-subunits Milligan, 2000; Guo et al., 2001; Wurch and Pauwels, 2001 ) have been employed to explore the details of topics as diverse as the relative intrinsic activity of different agonist ligands (Jackson et al., 1999) , the selectivity of receptors for closely related G proteins (Moon et al., 2001b) , and the regulation of post-translational acylation of both receptors and G proteins (Loisel et al., 1999; Stevens et al., 2001) . Herein, the use of such fusion proteins containing the human 5-HT 1A receptor and pertussis toxinresistant forms of G i -family G proteins allowed prior pertussis toxin treatment of the cells to define that ligand and RGS regulation of the high-affinity GTPase activity was a direct monitor only of effects on the fusion protein-linked G proteins. Because antagonist binding is generally insensitive to the G protein interaction state of receptors it is hardly surprising that the affinity for antagonist ligands was highly similar for each of the fusion constructs employed in these studies and that this was not altered by addition of the recombinant RGS proteins (Figs. 7 and 8C) .
Furthermore, because ligand occupancy of the 5-HT 1A receptor is required to suppress the effects of the RGS proteins on constitutive GTPase activity of the fusion proteins, it was also anticipated that the pEC 50 value for the ligands as inverse agonists should be in good agreement with measures of ligand affinity. Measures of pEC 50 were difficult to obtain for such ligands at the 5-HT 1A receptor-(Cys 351 Ile)G o1 ␣ construct in the absence of an RGS because the measurable effects of the ligands were small. Affinity estimates were, thus, of low precision. However, for the 5-HT 1A receptor-(Cys 351 Ile)G i1 ␣ construct, such estimates were not altered significantly by the presence of the RGS. This is a more complex issue for agonist ligands because we have previously noted that the presence of an RGS reduces the potency of high-efficacy agonists at the ␣ 2A -adrenoceptor, although it does not alter their binding affinity (Hoffmann et al., 2001) . When examining a range of ligands with inverse agonist activity at the 5-HT 1A receptor fusion proteins, it was clear that the rank order of potency was the same for their capacity to inhibit basal GTPase activity and their affinity to bind to the receptor with methiothepin Ͼϩ butaclamol Ͼ chlorpromazine. Furthermore, because the only effects of haloperidol on GTPase activity occurred at substantially higher concentrations than are consistent with ligand occupancy of the receptor (Fig. 11) , this indicates that these effects are not specific. Thus, over the pharmacologically relevant concentration range, haloperidol was shown as a true neutral ligand for the 5-HT 1A receptor.
The general strategy adopted in these studies should be suitable for any G i /G o -coupled receptor that possesses a degree of constitutive activity. Furthermore, although G s seems to be resistant to the effects of traditional RGS proteins, it is possible to employ chimeric G proteins to overcome this limitation. For example, the effects of vasopressin V 2 receptor agonists became sensitive to RGS regulation when the receptor was constructed into a fusion protein with a G i /G s chimera that is activated by the receptor and retains high affinity to bind RGS1 (Feng et al., 2002) .
These studies provide an entirely novel means of enhancing the sensitivity of studies on regulation of high-affinity GTPase activity and, thus, of examining the detailed characteristics of weak partial agonists and inverse agonists.
